Competition, page-49

https://www.stocktitan.net/news/PNT/point-biopharma-confirms-no-supply-shortages-of-177lu-pnt2002-for-dn26rgxjgfil.html

Clinical doses continue to be manufactured and shipped from the Company’s Indianapolis, Indiana facility

INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA targeted 177Lu-PNT2002 program remains on schedule and has not experienced any issues or delays related to clinical drug supply.

“Reliability is in our DNA,” said Dr. Joe McCann, CEO of POINT Biopharma. “POINT’s platform was designed from inception with a focus of ensuring the reliable delivery of next generation radiopharmaceuticals. The core reason reliability is so important to us is the narrow margin for error with radiopharmaceuticals; these drugs are manufactured just-in-time and only last for a few days. If you want patients to always receive their treatments, always on time, you need a redundant supply chain and manufacturing capabilities that can react in real time to unexpected changes. And that’s why we built POINT.”

POINT has built one of the industry’s most resilient medical isotope supply chains, which includes both external supply partners as well as internal isotope manufacturing capabilities. In addition to its manufacturing facility in Indianapolis, Indiana, POINT also maintains active relationships with radiopharmaceutical contract manufacturers to ensure redundant manufacturing capabilities. Establishing redundancy across every key business area is a pillar of POINT’s value proposition to physicians and patients, and to be resilient during rare reactor-related irradiation shortages and other similar radiopharmaceutical supply chain disruptions.

Recruitment and drug shipment to trial sites continue for the Company’s Phase 3 SPLASH trial (NCT04647526) evaluating PNT2002 for the treatment of pre-chemotherapy metastatic castration-resistant prostate cancer (mCRPC), currently enrolling patients across in North America and Europe. Site activations in all jurisdictions remain ongoing to expedite accrual, and the Company continues to expect to report top line data from SPLASH mid-2023.